Identifying Hepatitis B Carriers at Low Risk for Hepatocellular Carcinoma

Time-dependent events in natural history of occult hepatitis B virus infection: the importance of population-based long-term follow-up study with repeated measurements

Hepatitis B Surface Antigen Loss: Too Little, Too Late and the Challenge for the Future

A new role for an old marker, HBsAg

Viral Hepatitis in Liver Transplantation

Most cases of hepatocellular carcinoma (HCC) are associated with cirrhosis related to chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Changes in the time trends of HCC and most variations in its age-, sex-, and race-specific rates among different regions are likely to be related to differences in hepatitis viruses that are most prevalent in a population, the timing of their spread, and the ages of the individuals the viruses infect. Environmental, host genetic, and viral factors can affect the risk of HCC in individuals with HBV or HCV infection. This review summarizes the risk factors for HCC among HBV- or HCV-infected individuals, based on findings from epidemiologic studies and meta-analyses, as well as determinants of patient outcome and the HCC disease burden, globally and in the United States.

Natural history of chronic hepatitis B in Euro-Mediterranean and African Countries

Clinical utility in quantifying serum HBV DNA levels using PCR assays

American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy

Treatment options for chronic hepatitis B not responding to interferon

Management of patients with hepatitis B virus-induced cirrhosis

Eliminating cccDNA to cure hepatitis B virus infection

RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant

Navigating the Maze of Hepatitis B Treatments

NVR 3-778 Plus Pegylated Interferon-α Treatment for Chronic Hepatitis B Viral Infections: Could 1 + 1 = 3?

Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years